key: cord-0734738-ymni0pki authors: Sawadogo, Serge A.; Dighero-Kemp, Bonnie; Ouedraogo, Dieu-Donné; Hensley, Lisa; Sakandé, Jean title: How NETosis could drive “Post-COVID-19 syndrome” among survivors date: 2020-09-29 journal: Immunol Lett DOI: 10.1016/j.imlet.2020.09.005 sha: 41bd0e80df0c6f98b015e3f3f94165598d8aa681 doc_id: 734738 cord_uid: ymni0pki nan of virus replication based on virus-induced pathogenesis, the weak efficiency of antiviral drugs and the predominant hyperinflammatory symptoms is reorienting the pathophysiology through an immunopathogenesis. Acute respiratory distress syndrome associated with lung, heart, liver and kidney damage, thrombosis and disseminated intravascular coagulation, crosstalk for hyperactivation with complement system proteins and platelets, adaptive immune response disorientation and immune-crippling cytokine storm could all be neutrophil-driven during COVID- . After a grueling stay in resuscitation units, patients recovering from severe forms of COVID-19 experience after few days or weeks of remission, long and painful convalescence. This evolution can be interspersed with residual systemic inflammatory symptoms and sequelaes. COVID-19 survivors suffer from headaches, asthenia, arthromyalgia, tissue lesion sequelaes (lung, heart, and skin) and neuropsychopathologies. Other viral immune-driven diseases share with COVID-19 its features of hyperinflammatory immune response, coagulation disorders, and painful convalescence. In fact, such post-infection remnant inflammation and autoimmune-like relapse with rheumatoid arthritis, arthromyalgia, spondyloarthritis and uveitis has been described for Ebola virus disease [7] [8] [9] , and to a lesser degree Dengue fever [10] [11] and West Nile fever [12] [13] . In Wilson HW research, Post-Ebola Syndrome is reported among survivors during the first 1 to 12 weeks after being discharged from hospitalization. The frequency is estimated at 90% of Ebola survivors mainly among women (67%). The detection of auto-antibodies (anti-nuclear antibodies, anti-CCP, rheumatoid factor) in the blood of survivors strongly suggest residual autoreactive participation to inflammation and tissue lesions [14] . More concerning are the observed Post-Ebola sequelaes such as secondary amenorrhea, alopecia, blindness and deafness, which seem to be associated with more permanent immune-driven damages. Another intriguing similarity is that growing evidence suggests that SARS-CoV-2, like Ebola or Dengue, seems to trigger neutrophil-induced immunopathogenesis. Severe COVID-19 cases develop priming of neutrophils which matches a hyperinflammation state and severity in disease [15] : Analysis of haematologic parameters reveals that important neutrophilia [16] [22] . NETs release (NETosis) is a powerful mechanism of microbial destruction whereby neutrophils die and release digestive granules containing neutrophil elastase (NE) and myeloperoxidase (MPO) [23] . The concomitant and inflammatory release of autoantigens from dying neutrophils is increasingly a hallmark of autoimmune processes. As foreseen, NETosis participates in several tissue-specific and systemic autoimmune diseases [24] : systemic J o u r n a l P r e -p r o o f lupus erythemosus, antineutrophil cytoplasmic antibodies (ANCA) Vasculitis (AVV), rheumatoid arthritis, antiphospholipid syndrome, multiple sclerosis... In fact, NETosis is a singular immune response whereby immune cells, mainly neutrophils, are empowered to expel nuclear and cytoplasmic proteins in tissues and in the blood [23] [24] . Externalized neutrophil granule proteins, namely NE and MPO, are able to protectively lyse pathogens, yet also induce tissue damages. During this process neutrophils on one hand release several hidden auto-antigens as substrates for immunization, drive tissue damage and tissue-specific auto-antigens externalization; and on the other hand release danger-associated molecular patterns (DAMPs) that induce, perpetuate or increase cell damage based inflammation and immune stimulation. The efficient and quick clearance of those immune-unbeknown self-antigens through efferocytosis greatly contributes to maintain the tissue tolerance and/or the limitation of inflammation-related tissue damages [25] [24] . This happens when NETosis is excessive and is inefficiently cleared by regular efferocytosis. Infection-induced systemic inflammatory response syndrome (SIRS) is a particular situation giving immune cells the quitus to activate and eradicate the pathogens. This license to activation, the bystander activation, is not contained to protective effectors but also to other immune effector cells and even autoreactive B et T cells [26] . Bystander activation then operates to facilitate the activation of autoreactive cells and this ends normally without long-lasting autoimmune disease through resolution of the SIRS, cleaning of tissue damages and NETs, and finally suppressive brake by inducible regulatory cells. So, if NETosis is confirmed as the leading cause of severe and fatal evolution of COVID-19 as several research teams envision [1] [6] [21] [22] we must be prepared to observe a resurgence of a non-infectious inflammatory illness among convalescents : the "Post-COVID-19 Syndrome". Based on post-Ebola syndrome observations, women should be more at risk to develop this autoimmunelike syndrome [14] . Beyond clinical symptoms follow-up, biomarkers should be identified, monitored and extended to autoimmune marker exploration. The contemporaneous and residual neutrophilinduced inflammation and low-grade systemic inflammation state among convalescents should predict the eventual conversion to Post-COVID-19 Syndrome: hs-CRP, NE and MPO titrations, with sera remnant NETs - [27] . The titration and follow-up of several autoantibodies will strengthen the exploration when symptoms or biological disturbances appear. Anti-nuclear antibodies such as antihistone, together with anti-neutrophil cytoplasmic antibody -ANCA [28] , anti-cyclic citrullinated peptide [29] , rheumatoid factor [14] , and anti-NET antibodies -ANETA [30] are good candidates. Therapies controlling NETosis, NETs clearance and neutrophil recruitment should also be considered for management during a COVID-19 episode and for recovered convalescents [3] Targeting potential drivers of COVID-19: Neutrophil extracellular traps Complement in Hemolysis-and Thrombosis-Related Diseases Explore COVID-19 Marseille Immunopole group, Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis Orchestration of Adaptive T Cell Responses by Neutrophil Granule Contents Severe immunosuppression and not a cytokine storm characterize COVID-19 infections SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure Ebola virus infection induces autoimmunity against dsDNA and HSP60 Post-Ebola Syndrome among Ebola Virus Disease Survivors in Montserrado County Ebola virus disease: An emerging and re-emerging viral threat Post-infectious fatigue syndrome in dengue infection Detrimental Role of Neutrophil Extracellular Traps during Dengue Virus Infection A paradoxical role for neutrophils in the pathogenesis of West Nile virus West Nile Virus infection triggering autoimmune encephalitis: Pathophysiological and therapeutic implications Ebola-Specific CD8+ and CD4+ T Cell Responses in Sierra Leonean Ebola Virus Survivors with and without Post Viral Sequelae Prognostic value of C-reactive protein in patients with COVID-19 Hematological findings in coronavirus disease 2019: indications of progression of disease Hematological features of persons with COVID-19 Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis Neutrophil extracellular traps in COVID-19 Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19, Cells Neutrophil extracellular traps in immunity and disease Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses The Role of Efferocytosis in Autoimmune Diseases Bystander activation and autoimmunity Increased levels of neutrophil extracellular trap remnants in the serum of patients with rheumatoid arthritis Intrinsically Distinct Role of Neutrophil Extracellular Trap Formation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Compared to Systemic Lupus Erythematosus Human host defence peptide LL37 and anti-cyclic citrullinated peptide antibody in early inflammatory arthritis, RMD Open Autoantibodies to neutrophil extracellular traps represent a potential serological biomarker in rheumatoid arthritis Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial